Intellia Therapeutics Just Notched Another Win. So Why Did Its Stock Fall 18% in 1 Day?
Sometimes with biotech stocks, what a company considered to be good news clashes with what the market is expecting. That was true on Oct. 24 when Intellia Therapeutics (NASDAQ: NTLA) announced some positive new clinical trial data only to see its stock slide by 18% -- and the price hasn't fully recovered as of yet.
What's causing this disconnect, and could Intellia Therapeutics be a buy now? We'll start by answering the first question.
One of Intellia's most advanced programs is its candidate called NTLA-2002, which is in phase 3 clinical trials to treat hereditary angioedema (HAE). NTLA-2002 is a one-time gene editing therapy that's intended to fix the genetic basis for HAE permanently, effectively curing it.
Source Fool.com
Intellia Therapeutics Inc Stock
€8.35
8.040%
The stock is one of the favorites of our community with 25 Buy predictions and 3 Sell predictions.
Based on the current price of 8.35 € the target price of 49 € shows a potential of 486.97% for Intellia Therapeutics Inc which would more than double the current price.
